Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease

References

• Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009; 15:1-7; PMID:19116041; https://doi.org/10.3201/eid1501.080311
   PubMed Web of Science ®Google Scholar
• Monath TP. Japanese encephalitis – a plague of the Orient. New Engl J Med 1988; 319:641-3; https://doi.org/10.1056/NEJM198809083191009
   PubMed Web of Science ®Google Scholar
• World Health Organization. http://www.who.int/mediacentre/factsheets/fs386/en/. Accessed 23 September 2016.
   Google Scholar
• Rosen L, Rosenboom LE, Gubler DJ, Lien JC, Chaniotis BN. Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses. Am J Trop Med Hyg 34:603-15. PMID:2860816
   PubMed Web of Science ®Google Scholar
• Reuben R, Tewari S, Hiriyan J, Akiyama J. Illustrated keys to species of Culex (Culex) associated with Japanese encephalitis in Southeast Asia (Diptera: Culicidae). Mosquito Systematics 1994; 26:75-96
   Google Scholar
• Liu W, Gibbons RV, Kari K, Clemens JD, Nisalak A, Marks F, Xy ZY. Risk factors of Japanese encephalitis: a case control study. Epidemiol Infect 2010; 138:1292-7; PMID:20109262; https://doi.org/10.1017/S0950268810000063
   PubMed Web of Science ®Google Scholar
• Richards EE, Masuoka P, Brett-Major D, Smith M, Klein TA, Kim HC, Anyamba A, Grieco J. The relationship between mosquito abundance and rice field density in the Republic of Korea. Int J Health Geogr 2010; 9:32; PMID:20573242; https://doi.org/10.1186/1476-072X-9-32
   PubMed Web of Science ®Google Scholar
• Scherer WF, Buescher EL. Ecological studies of Japanese encephalitis virus in Japan. I. Introduction. Am J Trop Med 1959; 8:644-50
   PubMed Web of Science ®Google Scholar
• Buescher EL, Scherer WF, McLure HE, Moyer JT, Rosenberg MZ, Yoshii M, Okada Y. Ecological studies of Japanese encephalitis virus in Japan. IV. Avian infection. Am J Trop Med 1959; 8:678-88
   PubMed Web of Science ®Google Scholar
• Scherer WF, Moyer JT, Izumi T, Gresser I, McCown J. Ecological studies of Japanese encephalitis virus in Japan. VI. Swine infection. Am J Trop Med 1959; 8:698-706
   PubMed Web of Science ®Google Scholar
• Scherer WF, Buescher EL. Ecological studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions. Am J Trop Med 1959; 8:719-22
   PubMed Web of Science ®Google Scholar
• Le Flohic G, Porphyre V, Barbazan P, Gonzalez J-P. Review of climate, landscape, and viral genetics as drivers of Japanese encephalitis virus ecology. PLoS Negl Trop Dis 2013; 7:e2208; PMID:24069463; https://doi.org/10.1371/journal.pntd.0002208
   PubMed Web of Science ®Google Scholar
• Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011; 89:766-74; PMID:22084515; https://doi.org/10.2471/BLT.10.085233
   PubMed Web of Science ®Google Scholar
• Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002; 267:171-94. PMID:12082989
   PubMed Web of Science ®Google Scholar
• Kim J-K, Kim J-M, Song B-H, Yun S-I, Yun G-N, Byun S-J, Lee Y-N. Profiling of Viral Proteins Expressed from the Genomic RNA of Japanese Encephalitis Virus Using a Panel of 15 Region-Specific Polyclonal Rabbit Antisera: Implications for Viral Gene Expression. PLoS ONE 2015; 10:e0124318; PMID:25915765; https://doi.org/10.1371/journal.pone.0124318
   PubMed Web of Science ®Google Scholar
• Apte-Sengupta W, Sirohi D, Kuhn RJ. Coupling of replication and assembly in flaviviruses. Curr Opin Virol 2014; 9:134-42; PMID:25462445; https://doi.org/10.1016/j.coviro.2014.09.020
   PubMed Web of Science ®Google Scholar
• Tsarev SA, Sanders ML, Vaughn DW, Innis BL. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 2000; 18(Suppl 2):36-43; PMID:10821972; https://doi.org/10.1016/S0264-410X(00)00039-6
   PubMed Web of Science ®Google Scholar
• Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg 2001; 65:242-51. PMID:11561712
   PubMed Web of Science ®Google Scholar
• Morita K. Molecular epidemiology of Japanese encephalitis in East Asia. Vaccine 2009; 27:7131-2; PMID:19799848; https://doi.org/10.1016/j.vaccine.2009.09.051
   PubMed Web of Science ®Google Scholar
• Do LP, Bui TM, Hasebe F, Morita K, Phan NT. Molecular epidemiology of Japanese encephalitis in northern Vietnam, 1964–2011. Virol J 2015; 12:51; PMID:25889499; https://doi.org/10.1186/s12985-015-0278-4
   PubMed Web of Science ®Google Scholar
• Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000; 18(Suppl 2):26-32; PMID:10821970; https://doi.org/10.1016/S0264-410X(00)00038-4
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckegnooghe A, Gailhardou S, Boaz M, Feroldi E. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naïve 12- to 24-month-olds: multicentre randomized controlled trial. Pediatr Infect Dis 2010; 29:1111-7; https://doi.org/10.1097/INF.0b013e3181f68e9c
   Google Scholar
• Fulmali PV, Sapkal GN, Athawale S, Gore MM, Mishra AC, Bondre VP. Introduction of Japanese encephalitis virus genotype I, India. Emerg Infect Dis 2011; 17:319-21; PMID:21291622; https://doi.org/10.3201/eid1702.100815
   PubMed Web of Science ®Google Scholar
• Fan YC, Chen JM, Chiu HC, Chen YY, Lin JW, Shih CC, Chen CM, Chang CC, Chang GJ, Chiou SS. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis 2012; 6:e1834; PMID:23029592; https://doi.org/10.1371/journal.pntd.0001834
   PubMed Web of Science ®Google Scholar
• Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis 2013; 56:267-70; PMID:23074319; https://doi.org/10.1093/cid/cis883
   PubMed Web of Science ®Google Scholar
• Bonaparte M, Dweik B, Feroldi E, Meric C, Bouckenooghe A, Hildreth S, Hu B, Yoksan S, Boaz M. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis 2014; 14:156; PMID:24656175; https://doi.org/10.1186/1471-2334-14-156
   PubMed Web of Science ®Google Scholar
• Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study. Vaccine 2014; 32:119-23; https://doi.org/10.1016/j.vaccine.2013.10.055
   Web of Science ®Google Scholar
• Ye Q, Li XF, Zhao H, Deng YQ, Xu YP, Wang HY, Liang GD, Qin CF. Reduction of neutralization antibody against heterologous circulating strains in adults immunized with Japanese encephalitis live vaccine. Hum Vaccin Immunother 2014; 10:2704-5; PMID:25483500; https://doi.org/10.4161/hv.29509
   PubMed Web of Science ®Google Scholar
• Singh A, Mitra M, Sampath G, Venugopal P, Rao JV, Krishnamurthy B, Gupta MK, Sri Krishna S, Sudhakar B, Rao NB, et al. A Japanese encephalitis vaccine from India induces durable and cross-reactive immunity against temporally and spatially wide-ranging global field strains. J Infect Dis 2015; 212:715-25; PMID:25601942; https://doi.org/10.1093/infdis/jiv023
   PubMed Web of Science ®Google Scholar
• Takhampunya R, Kim HC, Tippayachai B, Kengluecha A, Klein TA, Lee WJ, Grieco J, Evans BP. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol J 2011; 8:449; PMID:21943222; https://doi.org/10.1186/1743-422X-8-449
   PubMed Web of Science ®Google Scholar
• Ferguson M, Johnes S, Li L, Heath A, Barrett A. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines – report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 2008; 36:111-6; PMID:17892945; https://doi.org/10.1016/j.biologicals.2007.07.002
   PubMed Web of Science ®Google Scholar
• Trent DW, Minor P, Jivapaisarnpong T, Shin J. WHO working group on the quality, safety and efficacy of Japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21–23 February 2012. Biologicals 2013; 41:450-7; PMID:23891495; https://doi.org/10.1016/j.biologicals.2013.06.001
   PubMed Web of Science ®Google Scholar
• Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008; 8:95-106; PMID:18081539; https://doi.org/10.1517/14712598.8.1.95
   PubMed Web of Science ®Google Scholar
• Li MH, Fu SH, Chen WX, Wang HY, Guo YH, Liu QY, Li YX, Luo HM, Da W, Duo Ji DZ, et al. Genotype V of Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 2011; 5:e1231; PMID:21750744; https://doi.org/10.1371/journal.pntd.0001231
   PubMed Web of Science ®Google Scholar
• Mohammed MA, Galbraith SE, Radford AD, Dove W, Takasaki T, Kurane I, Solomon T. Molecular phylogenetic and evolutionary analyses of Muar strain of Japanese encephalitis virus reveal it is the missing fifth genotype. Infect Genet Evol 2011; 11:855-62; PMID:21352956; https://doi.org/10.1016/j.meegid.2011.01.020
   PubMed Web of Science ®Google Scholar
• Seo HJ, Kim HC, Klein TA, Ramey AM, Lee JH, Kyung SG, Park JY, Cho YS, Cho IS, Yeh JY. Molecular detection and genotyping of Japanese encephalitis virus in mosquitoes during a 2010 outbreak in the Republic of Korea. PLoS ONE 2013; 8:e55165; PMID:23390520; https://doi.org/10.1371/journal.pone.0055165
   PubMed Web of Science ®Google Scholar
• Kim H, Cha GW, Jeong YE, Lee WG, Chang KS, Roh JY, Yang SC, Park MY, Park C, Shin EH. Detection of Japanese encephalitis virus genotype V in Culex orientalis and Culex pipiens (Diptera: Culicidae) in Korea. PLoS ONE 2015; 10:e0115647
   Web of Science ®Google Scholar
• Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10(Suppl 12):S98-109; PMID:15577938; https://doi.org/10.1038/nm1144
   PubMed Web of Science ®Google Scholar
• Schuh AJ, Ward MJ, Brown AJ, Barrett AD. Phylogeography of Japanese encephalitis virus: genotype associated with climate. PLoS Negl Trop Dis 2013; 7:e2411; PMID:24009790; https://doi.org/10.1371/journal.pntd.0002411
   PubMed Web of Science ®Google Scholar
• Nitatpattana N, Dubot-Peres Z, Gouilh MA, Souris M, Barbazan P, Yoksan S, de Lamballerie X, Gonzalez JP. Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis 2008; 14:1762-5; PMID:18976565; https://doi.org/10.3201/eid1411.080542
   PubMed Web of Science ®Google Scholar
• Han N, Adams J, Chen P, Gou ZY, Zhong XF, Fang W, Li N, Wen L, Tao XY, Yuan ZM, et al. Comparison of genotypes I and III in Japanese encephalitis virus reveals distinct differences in their genetic and host diversity. J Virol 2014; 88:11469-79; PMID:25056890; https://doi.org/10.1128/JVI.02050-14
   PubMed Web of Science ®Google Scholar
• Li MH, Fu SH, Chen WX, Wang HY, Cao YX, Liang GD. Molecular characterization of full-length genome of Japanese encephalitis virus genotype V isolated from Tibet, China. Biomed Environ Sci 2014; 27:231-9. PMID:24758751
   PubMed Web of Science ®Google Scholar
• Cao L, Fu S, Gao X, Li M, Cui S, Li X, Cao Y, Lei W, Lu Z, He Y, et al. Low protective efficacy of the current Japanese encephalitis vaccine against the emerging genotype 5 Japanese encephalitis virus. PLoS Negl Trop Dis 2016; 10:e0004686; PMID:27139722; https://doi.org/10.1371/journal.pntd.0004686
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Fonville JM, Gromowski GD, Arriaga JB, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science 2015; 349:1338-43; PMID:26383952; https://doi.org/10.1126/science.aac5017
   PubMed Web of Science ®Google Scholar
• Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A, Kieny MP. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, Thailand. Vaccine 2005; 23:2689-95; PMID:15841565; https://doi.org/10.1016/j.vaccine.2004.11.040
   PubMedGoogle Scholar
• van Gessel Y, Klade CS, Putnak R, Formica A, Krasaesub S, Spruth M, Cena B, Tungtaeng A, Gettayacamin M, Dewasthaly S. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO®) induced neutralizing antibody titres. Vaccine 2011; 29:5925-31; PMID:21723353; https://doi.org/10.1016/j.vaccine.2011.06.062
   PubMed Web of Science ®Google Scholar
• Konishi E, Kurane I, Mason PW, Innis BL, Ennis FA. Japanese encephalitis virus-specific proliferative responses of human peripheral blood T lymphocytes. Am J Trop Med Hyg 1995; 53:278-83. PMID:7573713
   PubMed Web of Science ®Google Scholar
• Aihara H, Takasaki T, Matsutani T, Suzuki R, Kurane I. Establishment and characterization of Japanese encephalitis virus-specific, human CD4+ T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J Virol 1998; 72:8032-6. PMID:9733842
   PubMed Web of Science ®Google Scholar
• Aihara H, Takasaki T, Toyosaki-Maeda T, Suzuki R, Okuno Y, Kurane I. T-cell activation and induction of antibodies and memory T cells by immunization with inactivated Japanese encephalitis vaccine. Viral Immunol. 2000; 13:179-86; PMID:10892998; https://doi.org/10.1089/vim.2000.13.179
   PubMed Web of Science ®Google Scholar
• Kumar P, Sulochana P, Nirmala G, Haridattatreya M, Satchidanandam V. Conserved amino acids 193–324 of non-structural protein 3 are a dominant source of peptide determinants for CD4+ and CD8+ T cells in a healthy Japanese encephalitis virus-endemic cohort. J Gen Virol 2004; 85:1131-43; PMID:15105530; https://doi.org/10.1099/vir.0.19698-0
   PubMed Web of Science ®Google Scholar
• Turtle L, Bali T, Boxton G, Chib S, Chan S, Soni M, Hussain M, Isenman H, Fadnis P, Venkataswamy MM, et al. Huma T cell responses to Japanese encephalitis virus in health and disease. J Exp Med 2016; 213:1331-52; PMID:27242166; https://doi.org/10.1084/jem.20151517
   PubMed Web of Science ®Google Scholar
• Koprowski H, Cox HR. Propagation of Japanese B encephalitis virus in the developing chick embryo. J Immunol 1946; 52:171-86. PMID:21018820
   PubMed Web of Science ®Google Scholar
• Warren J, Smadel JE, Rasmussen AF. The antibody response in human beings inoculated with Japanese encephalitis vaccine, chick embryo type. J Immunol 1948; 58:211-21. PMID:18905195
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Kitaoka M, Burns KF. Evaluation of Japanese B encephalitis vaccine. II. Serologic response following subcutaneous and intradermal administration. Am J Hyg 1956; 63:228-9
   PubMed Web of Science ®Google Scholar
• Ando K, Satterwhite JP. Evaluation of Japanese B encephalitis vaccine. III. Okayama field trial, 1946–1949. Am J Hyg 1956; 63:230-7
   PubMed Web of Science ®Google Scholar
• Tigertt WD, Berge TO, Burns KF, Satterwhite JP. Evaluation of Japanese B encephalitis vaccine. IV. Pattern of serologic response to vaccination over a five-year period in an endemic area (Okayama, Japan). Am J Hyg 1956; 63:238-49
   PubMed Web of Science ®Google Scholar
• Sabin AB. Epidemic encephalitis in military personnel; isolation of Japanese B encephalitis virus in Okinawa in 1945, serologic diagnosis, clinical manifestations, epidemiologic aspects and use of mouse brain vaccine. J Am Med Assoc 1947; 133:281-93; PMID:20280992; https://doi.org/10.1001/jama.1947.02880050001001
   PubMed Web of Science ®Google Scholar
• Hammon WM, Darwish MA, Rhim JS, Sather GE, Yohn DS, Mittelman A, Deverson E, Soyka JP. Studies on Japanese B encephalitis virus vaccines from tissue culture. V. Response of man to live, attenuated strain OCT-541 virus vaccine. J Immunol 1966; 96:518-24
   PubMed Web of Science ®Google Scholar
• Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 1990; 161:878-82; PMID:2324539; https://doi.org/10.1093/infdis/161.5.878
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Hoke CH, McCown J, DeFraites RF, Takafuji ET, Diniega BM, Pang LW. Further experience with Japanese encephalitis vaccine. Lancet 1990; 335:972-3; PMID:1970043; https://doi.org/10.1016/0140-6736(90)91036-A
   PubMed Web of Science ®Google Scholar
• Defraites RF, Gambel JM, Hoke CH Jr., Sanchez JL, Withers BG, Karabatsos N, Shope RE, Tirrell S, Yoshida I, Takagi M. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimen. Am J Trop Med Hyg 61:288-93. PMID:10463681
   PubMed Web of Science ®Google Scholar
• Hsu TC, Chow LP, Wei HY, Chen CL, Hsu ST. A controlled field trial for an evaluation of effectiveness of mouse-brain Japanese encephalitis vaccine. Taiwan Yi Xue Hui Za Zhi. 1971; 70:55-62. PMID:4325804
   PubMedGoogle Scholar
• Kanamitsu J, Hashimoto N, Urasawa S, Katsurada M, Kimura H. A field trial with an improved Japanese encephalitis vaccine in a nonendemic area of the disease. Biken J 1970; 13:313-28. PMID:5510351
   PubMedGoogle Scholar
• Fukunaga T, Rojanasuphot S, Wungkorbkiat S, Thammanichanon A, Kan T. Japanese encephalitis vaccination in Thailand. Biken J 1974; 17:21-31. PMID:4368852
   PubMedGoogle Scholar
• Juang RF, Okuno Y, Fukunaga T, Tadano M, Fukai K, Baba K, Tsuda N, Yamada A, Yabuuchi H. Neutralizing antibody responses to Japanese encephalitis vaccine in children. Biken J 1983; 26:25-34. PMID:6626137
   PubMedGoogle Scholar
• Rao Bhau LN, Singh G, Gowal D, Saxena SN, Kobayashi M, Oya A, Yoshioka I. Safety & efficacy of Japanese encephalitis vaccine produced in India. Indian J Med Res 1988; 88:301-7. PMID:2852169
   PubMed Web of Science ®Google Scholar
• Nimmannitya S, Hutamai S, Kalyanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J Trop Med Public Health 1995; 26:689-93. PMID:9139377
   PubMedGoogle Scholar
• Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988; 319:608-14; PMID:2842677; https://doi.org/10.1056/NEJM198809083191004
   PubMed Web of Science ®Google Scholar
• Ku CC, King CC, Lin CY, Hsu HC, Chen LY, Yueh YY, Chang GJ. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol 1994; 44:122-31; PMID:7852952; https://doi.org/10.1002/jmv.1890440204
   PubMed Web of Science ®Google Scholar
• Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J Trop Med Public Health 1995; 26:689-93. PMID:9139377
   PubMedGoogle Scholar
• Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis virus strains. Vaccine 2000; 18(Suppl 2):33-5; PMID:10821971; https://doi.org/10.1016/S0264-410X(00)00041-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Wkly Epidemiol. Record 2005; 80:241-48
   Google Scholar
• Centers for Disease Control and Prevention. Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine – Advisory Committee on Immunization Practices. Morb Mortal WklyRep 2011; 60:661-3
   PubMedGoogle Scholar
• Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D. WHO informal consultation group. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1–2 June 2006. Vaccine 2007; 25:5233-43; PMID:17590244; https://doi.org/10.1016/j.vaccine.2007.05.034
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Inactivated Japanese encephalitis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42(RR-1):1-15
   Google Scholar
• Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000; 18:2963-9
   PubMed Web of Science ®Google Scholar
• Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Imunol Allergy Clin North Am 2003; 23:665-97; https://doi.org/10.1016/S0889-8561(03)00102-4
   PubMed Web of Science ®Google Scholar
• Plesner AM, Ronne T, Wachmann H. Case-control study of allergic reactions to Japanese encephalitis vaccine. Vaccine 2000; 18:1830-6; PMID:10699331; https://doi.org/10.1016/S0264-410X(99)00403-X
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. Vaccine 1998; 16:68-9; PMID:9607011; https://doi.org/10.1016/S0264-410X(97)00152-7
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Yoshida M, Kuroda W, Harayama O, Matsunga Y, Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 1997; 15:121-2; PMID:9066026; https://doi.org/10.1016/S0264-410X(96)00170-3
   PubMed Web of Science ®Google Scholar
• Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, Wu TX, Yu HJ, Liu QM, Karabatsos N, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case control study. Lancet 1996; 347:1583-6; PMID:8667866; https://doi.org/10.1016/S0140-6736(96)91075-2
   PubMed Web of Science ®Google Scholar
• Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 2010; 28:3635-41; PMID:20226891; https://doi.org/10.1016/j.vaccine.2010.02.105
   PubMed Web of Science ®Google Scholar
• Yun SI, Song BH, Polejaeva IA, Davies CJ, White KL, Lee YM. Comparison of the live-attenuated Japanese encephalitis vaccine SA14-14-2 strain with its pre-attenuated virulent parent SA14 strain: similarities and differences in vitro and in vivo. J Gen Virol 2016; 97:2575-91; PMID:27498826; https://doi.org/10.1099/jgv.0.000574
   PubMed Web of Science ®Google Scholar
• Xin YY, Ming ZG, Peng GY, Jian A, Min LH. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 1988; 39:214-7. PMID:2841880
   PubMed Web of Science ®Google Scholar
• Luo D, Yin H, Xili L, Song J, Wang Z. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. Southeast Asian J Trop Med Public Health 1994; 25:643-6. PMID:7667706
   PubMedGoogle Scholar
• Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. Vaccine 2000; 18(Suppl 2):1-25; PMID:10821969; https://doi.org/10.1016/S0264-410X(00)00037-2
   PubMedGoogle Scholar
• Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine 1999; 17:2259-64; PMID:10403593; https://doi.org/10.1016/S0264-410X(99)00006-7
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lee SY, Kim KH, Kim DS, Cha SH, Jo DS, Kang JH. The immunogenicity and safety of the live-attenuated SA14-14-2 Japanese encephalitis vaccine given with a two-dose primary schedule in children. J Korean Med Sci 2015; 30:612-6; PMID:25931793; https://doi.org/10.3346/jkms.2015.30.5.612
   PubMed Web of Science ®Google Scholar
• Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. Efficacy of single-dose SA14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358:791-5; PMID:11564484; https://doi.org/10.1016/S0140-6736(01)05967-0
   PubMed Web of Science ®Google Scholar
• Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005; 366:1375-8; PMID:16226615; https://doi.org/10.1016/S0140-6736(05)67567-8
   PubMed Web of Science ®Google Scholar
• Wijesinghe PR, Abeysinghe MR, Yoksan S, Yao Y, Zhou B, Zhang L, Fleming JA, Marfin AA, Victor JC. Vaccine 2016; 34:5923-8
   PubMed Web of Science ®Google Scholar
• Vashishtha VM, Kalra A, Bose A, Choudhury P, Yewale VN, Bansal CP, Gupta SG. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years – India, 2013 and updates on immunization. Indian Pediatrics 2013; 50:1095-108; PMID:24413503; https://doi.org/10.1007/s13312-013-0292-9
   PubMed Web of Science ®Google Scholar
• Ni H, Burns NJ, Chang GJ, Zhang MJ, Wills MR, Trent DW, Sanders PG, Barrett AD. Comparison of nucleotide and deduced amino acid sequence of the 5′ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J Gen Virol 1994; 75:1505-10; PMID:8207417; https://doi.org/10.1099/0022-1317-75-6-1505
   PubMed Web of Science ®Google Scholar
• Ni H, Chang GJ, Xie H, Trent DW, Barrett AD. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol 1995; 76:409-13; PMID:7844560; https://doi.org/10.1099/0022-1317-76-2-409
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Firestone CY, Bustos-Arriaga J, Whitehead SS. Genetic and phenotypic properties of Vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice. Am J Trop Med Hyg 2015; 92:98-107; PMID:25311701; https://doi.org/10.4269/ajtmh.14-0427
   PubMed Web of Science ®Google Scholar
• Nitayaphan S, Grant JA, Chang GJ, Trent DW. Nucleotide sequence of the virulence SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA14-14-2. Virology 1990; 177:541-52; PMID:2371768; https://doi.org/10.1016/0042-6822(90)90519-W
   PubMed Web of Science ®Google Scholar
• Aihara S, Rao CM, Yu YX, Lee T, Watanabe K, Komiya T, Sumiyoshi H, Hashimoto H, Nomoto A. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes 1991; 5:95-109; PMID:1829286; https://doi.org/10.1007/BF00571925
   PubMed Web of Science ®Google Scholar
• Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus / Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 2001; 75:934-42; PMID:11134306; https://doi.org/10.1128/JVI.75.2.934-942.2001
   PubMed Web of Science ®Google Scholar
• Yun SI, Song BH, Kim JK, Yun GN, Lee EY, Li L, Kuhn RJ, Rossmann MG, Morrey JD, Lee YM. A molecularly cloned, live-attenuated Japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the IJ hairpin on the viral E glycoprotein determines neurovirulence in mice. PLoS Pathog. 2014; 10:e1004290; PMID:25077483; https://doi.org/10.1371/journal.ppat.1004290
   PubMed Web of Science ®Google Scholar
• Ye Q, Li XF, Zhao H, Li SH, Deng YQ, Cao RY, Song KY, Wang HJ, Uua RH, Yu YX, et al. A single nucleotide mutation in NS2A of Japanese encephalitis live vaccine virus (SA14-14-2) ablates NS1′ formation and contributes to attenuation. J Gen Virol 2012; 93:1959-64; PMID:22739060; https://doi.org/10.1099/vir.0.043844-0
   PubMed Web of Science ®Google Scholar
• Wang J, Li X, Gu J, Fan Y, Zhao P, Cao R, Chen P. The A66G back mutation in NS2A of JEV SA14-14-2 strain contributes to production of NS1′ protein and the secreted NS1′ can be used for diagnostic biomarker for virulent virus infection. Infect Genet Evol 2015; 36:116-25; PMID:26384477; https://doi.org/10.1016/j.meegid.2015.09.013
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin H, Zhu Q, Wu C, Zhao Z, Zheng H. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012. Vaccine 2014; 32:1768-73; PMID:24503272; https://doi.org/10.1016/j.vaccine.2013.11.107
   PubMed Web of Science ®Google Scholar
• Yang D, Li XF, Ye Q, Wang HJ, Deng YQ, Zhu SY, Zhang Y, Li SH, Qin CF. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine 2014; 32:2675-81; PMID:24709585; https://doi.org/10.1016/j.vaccine.2014.03.074
   PubMed Web of Science ®Google Scholar
• Jia N, Zhao QM, Guo XF, Cheng JX, Wu C, Zuo SQ, Dai PF, Zhao JY, Zhang JS. Encephalitis temporally associated with live attenuated Japanese encephalitis vaccine: four case reports. BMC Infect Dis 2011; 11:344; PMID:22168358; https://doi.org/10.1186/1471-2334-11-344
   PubMed Web of Science ®Google Scholar
• Fan JM, Luo J, Chen L, Teng M, Bu D, Wang FY, Wang L, Wang CQ, Zhang GP. Genetic analysis of strains of Japanese encephalitis virus isolated from swine in central China. Virus Genes 2010; 40:357-61; PMID:20213486; https://doi.org/10.1007/s11262-010-0464-9
   PubMed Web of Science ®Google Scholar
• Yoshida I, Takagi M, Inokuma E, Goda H, Ono K, Takaku K, Oku J, Kunita N, Amano T, Okuno Y. Establishment of an attenuated ML-17 strain of Japanese encephalitis virus. Biken J. 1981; 24:47-67. PMID:6272690
   PubMedGoogle Scholar
• Shah PS, Tanaka M, Khan AH, Mathenge EG, Fuke I, Takagi M, Igarashi A, Morita K. Molecular characterization of attenuated Japanese encephalitis live vaccine strain ML-17. Vaccine 2006; 24:402-11; PMID:16303214; https://doi.org/10.1016/j.vaccine.2005.10.048
   PubMed Web of Science ®Google Scholar
• Cao JX, Ni H, Wills MR, Campbell GA, Sil BK, Ryman KD, Kitchen I, Barrett AD. Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice. J Gen Virol 1995; 76:2757-64; PMID:7595383; https://doi.org/10.1099/0022-1317-76-11-2757
   PubMed Web of Science ®Google Scholar
• Sumiyoshi H, Tignor GH, Shope RE. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis 1995; 171:1144-51; PMID:7751689; https://doi.org/10.1093/infdis/171.5.1144
   PubMed Web of Science ®Google Scholar
• Lin YL, Liao CL, Yeh CT, Chang CH, Huang YL, Huang YY, Jan JT, Chin C, Chen LK. A highly attenuated strain of Japanese encephalitis virus induces a protective immune response in mice. Virus Res 1996; 44:45-56; PMID:8873412; https://doi.org/10.1016/0168-1702(96)01343-3
   PubMed Web of Science ®Google Scholar
• Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr., Innis BL, Vaughn DW. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. Am J Trop Med Hyg 1999; 60:343-9. PMID:10466959
   PubMed Web of Science ®Google Scholar
• Kanesa-Thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, Tang DB, Vaughn DW, Mason PW, Shope RE. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus – poxvirus vaccines in vaccine-nonimmune and vaccinia-immune humans. Vaccine 2000; 19:483-91; PMID:11027812; https://doi.org/10.1016/S0264-410X(00)00191-2
   PubMed Web of Science ®Google Scholar
• Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever / Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73:3095-101. PMID:10074160
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever – Japanese encephalitis virus (ChimerixVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 1999; 257:363-72; PMID:10329547; https://doi.org/10.1006/viro.1999.9695
   PubMed Web of Science ®Google Scholar
• Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, et al. Recombinant, chimeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999; 17:1869-82; PMID:10217584; https://doi.org/10.1016/S0264-410X(98)00487-3
   PubMed Web of Science ®Google Scholar
• Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18; PMID:11803060; https://doi.org/10.1016/S0264-410X(01)00457-1
   PubMed Web of Science ®Google Scholar
• Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett AD, Nichols R, Weltzin R, Arroyo J, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 2000; 74:1742-51; PMID:10644345; https://doi.org/10.1128/JVI.74.4.1742-1751.2000
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban B, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:32-49; https://doi.org/10.1016/j.vaccine.2009.09.098
   Web of Science ®Google Scholar
• Monath TP, Arroyo J, Levenbook I, Zhang ZX, Catalan J, Draper K, Guirakhoo F. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases visceropropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol 2002; 76:1932-43; PMID:11799188; https://doi.org/10.1128/JVI.76.4.1932-1943.2002
   PubMed Web of Science ®Google Scholar
• Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213-30; PMID:14551893; https://doi.org/10.1086/378356
   PubMed Web of Science ®Google Scholar
• Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 2000; 62:480-4. PMID:11220763
   PubMed Web of Science ®Google Scholar
• Torresi J, McCarthy K, Reroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials. Vaccine 2010; 28:7993-8000; PMID:20934459; https://doi.org/10.1016/j.vaccine.2010.09.035
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A. Single-dose live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012; 8:929-37; PMID:22777096; https://doi.org/10.4161/hv.20071
   PubMed Web of Science ®Google Scholar
• Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother 2013; 9:889-97; PMID:23442823; https://doi.org/10.4161/hv.23087
   PubMed Web of Science ®Google Scholar
• Feroldi E, Pancharoen C, Kosalaraksa P, Chokephaibulkit K, Boaz M, Meric C, Htagalung Y, Bouckenooghe A. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis 2014; 33:643-9; https://doi.org/10.1097/INF.0000000000000276
   Google Scholar
• Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, et al. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Hum Vaccin Immunother 2014; 10:2656-63; PMID:25483480; https://doi.org/10.4161/hv.29743
   PubMed Web of Science ®Google Scholar
• Janewongwirot P, Puthanakit T, Anuglufuengkitt S, Jantarabenjakul W, Phasomsap C, Chumket S, Yoksan S, Pancharoen C. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. Vaccine 2016; 34:5279-83; PMID:27628323; https://doi.org/10.1016/j.vaccine.2016.09.005
   PubMed Web of Science ®Google Scholar
• Sricharoenchai S, Chuenkitmongkol S, Phongsamart W, Bouckenooghe A, Wittawatmongkol O, Rungmaitree S, Chokephaibulkit K. Immunogenicity of a live attenuated chimeric Japanese encephalitis vaccine as a booster dose after primary vaccination with live attenuated SA14-14-2 vaccine: a Phase IV study in Thai children. Pediatr Infect Dis J 2016; 36:e45-7
   Google Scholar
• Darwish MA, Hammon WM. Studies on Japanese B encephalitis virus vaccines from tissue culture. 8. Formalin inactivated OCT-wild strain vaccine. J Immunol 1966; 97:506-11. PMID:4289222
   PubMed Web of Science ®Google Scholar
• Darwish MA, Hammon WM, Sather GE. Studies on Japanese B encephalitis virus vaccines from tissue culture. IX. Human response to a hamster-kidney tissue-culture inactivated vaccine. Am J Trop Med Hyg 1967; 16:364-70. PMID:4290334
   PubMed Web of Science ®Google Scholar
• Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, et al. A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007; 25:3445-53; PMID:17241714; https://doi.org/10.1016/j.vaccine.2006.12.046
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007; 370:1847-53; PMID:18061060; https://doi.org/10.1016/S0140-6736(07)61780-2
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Heinz FX, Kollaritsch H, Rendi-Wagner P, Jilma B, Tauber E. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008; 26:6151-6; PMID:18804132; https://doi.org/10.1016/j.vaccine.2008.08.056
   PubMed Web of Science ®Google Scholar
• Schuller E, Klade CS, Wolfl G, Kaltenbock A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009; 27:2188-93; PMID:19200452; https://doi.org/10.1016/j.vaccine.2008.12.062
   PubMed Web of Science ®Google Scholar
• Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834-9; PMID:19857447; https://doi.org/10.1016/j.vaccine.2009.10.024
   PubMed Web of Science ®Google Scholar
• Erra EO, Askling HH, Rombo L, Riutta J, Vene S, Yoksan S, Lindquist L, Pakkanen SH, Huhtamo E, Vapalahti O, et al. A single dose of Vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travellers primed with mouse brain-derived JE vaccines. Clin Infect Dis 2012; 55:825-34; PMID:22696017; https://doi.org/10.1093/cid/cis542
   PubMed Web of Science ®Google Scholar
• Woolpert T, Staples JE, Faix DJ, Nett RJ, Kosoy OI, Biggerstaff BJ, Johnson BW, Sracic M, Fischer M. Immunogenicity of one dose of Vero culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 2012; 30:3090-6; PMID:22406277; https://doi.org/10.1016/j.vaccine.2012.02.063
   PubMed Web of Science ®Google Scholar
• Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, Horikawa Y, Takeda K, Honda T, Kuzuhara S, et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002; 30:303-14; PMID:12421588; https://doi.org/10.1006/biol.2002.0345
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, Nishiyama K, Sugawara K, Takeda K, Honda T, et al. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 2003; 21:4519-26; PMID:14575762; https://doi.org/10.1016/S0264-410X(03)00506-1
   PubMed Web of Science ®Google Scholar
• Takeshita N, Lim CK, Mizuno Y, Shimbo T, Kotaki A, Ujiie M, Hayakawa K, Kato Y, Kanagawa S, Kaku M, et al. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults. J Infect Chemother 2014; 20:238-42; PMID:24485326; https://doi.org/10.1016/j.jiac.2013.11.010
   PubMed Web of Science ®Google Scholar
• Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Manazue J, Fuke I, Ishikawa T, Okuno Y, Ueda S. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine 2012; 30:2329-35; PMID:22306856; https://doi.org/10.1016/j.vaccine.2012.01.054
   PubMed Web of Science ®Google Scholar
• Okada K, Iwasa T, Namazue J, Akechi M, Ueda S, JE Vaccine Clinical Study Group. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated) (JEBIK®V) in children. Vaccine 2012; 30:5967-72; PMID:22841478; https://doi.org/10.1016/j.vaccine.2012.07.034
   PubMed Web of Science ®Google Scholar
• Yun KW, Lee HJ, Kang JH, Eun BW, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, et al. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial. BMC Infect Dis 2015; 15:7; PMID:25567119; https://doi.org/10.1186/s12879-014-0744-4
   PubMed Web of Science ®Google Scholar
• Kim DS, Jang GC, Cha SH, Choi SH, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Bang J, et al. Immunogenicity and safety of a booster dose of a live attenuated Japanese encephalitis chimeric vaccine given 1 year after primary immunization in healthy children in the Republic of Korea. Pediatr Infect Dis J 2016; 35:e60-4; PMID:26535878; https://doi.org/10.1097/INF.0000000000000967
   PubMed Web of Science ®Google Scholar
• Miyazaki C, Okada K, Ozaki T, Hirose M, Iribe K, Yokote H, Ishikawa Y, Togashi T, Ueda K. Phase III clinical trials comparing the immunogenicity and safety of the Vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain. Clin Vaccine Immunol 2014; 21:188-95; PMID:24334689; https://doi.org/10.1128/CVI.00377-13
   PubMed Web of Science ®Google Scholar
• Toriniwa H, Komiya T. Comparison of viral glycosylation using lectin blotting with Vero cell-derived and mouse brain-derived Japanese encephalitis vaccines. Vaccine 2011; 29:1859-62; PMID:21195800; https://doi.org/10.1016/j.vaccine.2010.12.038
   PubMed Web of Science ®Google Scholar
• Huang CH. Studies of Japanese encephalitis in China. Adv Virus Res 1982; 27:71-101
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Hasegawa H, Oyama T, Tamai T, Kusaba T. Antigenic analysis of Japanese encephalitis virus by using monoclonal antibodies. Infect Immun 1984; 44:117-23. PMID:6200438
   PubMed Web of Science ®Google Scholar
• Satake Y, Hasegawa H, Yoshida M, Kobayashi Y. Isolation and anti-Beijing-1 group-specific monoclonal antibody and antigenic analysis of Japanese encephalitis viruses in India. Vaccine 1994; 12:723-6; PMID:8091850; https://doi.org/10.1016/0264-410X(94)90222-4
   PubMed Web of Science ®Google Scholar
• Banerjee K. Certain characteristics of Japanese encephalitis virus strains by neutralization test. Indian J Med Res 1986; 83:243-50. PMID:3733180
   PubMed Web of Science ®Google Scholar
• Gore MM, Gupta AK, Ayachit VM, Athawale SS, Ghosh SN, Banerjee K. Selection of a neutralization-escape variant strain of Japanese encephalitis virus using monoclonal antibody. Indian J Med Res 1990; 91:231-3. PMID:1697849
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yoshida M, Fujita S, Kobayashi Y. Comparison of structural proteins among antigenically different Japanese encephalitis virus strains. Vaccine 1994; 12:841-4; PMID:7975862; https://doi.org/10.1016/0264-410X(94)90294-1
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yoshida M, Kobayashi Y, Fujita S. Antigenic analysis of Japanese encephalitis viruses in Asia by using monoclonal antibodies. Vaccine 1995; 13:1713-21; PMID:8719524; https://doi.org/10.1016/0264-410X(95)00099-M
   PubMed Web of Science ®Google Scholar
• Wu SC, Lian WC, Hsu LC, Wu YC, Liau MY. Antigenic characterization of nine wild-type Taiwanese isolates of Japanese encephalitis virus as compared with two vaccine strains. Virus Res. 1998; 55:83-91; PMID:9712514; https://doi.org/10.1016/S0168-1702(98)00037-9
   PubMed Web of Science ®Google Scholar
• Kang BK, Hwang JM, Moon H, Han SY, Kim JM, Yang DK, Park BK, Song D. Comparison of the antigenic relationship between Japanese encephalitis virus genotypes 1 and 3. Clin Exp Vaccine Res 2016; 5:26-30; PMID:26866021; https://doi.org/10.7774/cevr.2016.5.1.26
   PubMed Web of Science ®Google Scholar
• Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol 2003; 77:309-8; PMID:12477836; https://doi.org/10.1128/JVI.77.5.3091-3098.2003
   PubMed Web of Science ®Google Scholar
• Ma SP, Yoshida Y, Makino Y, Tadano M, Ono T, Ogawa M. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 2003; 69:151-4. PMID:13677370
   PubMed Web of Science ®Google Scholar
• Nga PT, del Carmen Parquet M, Cuong VD, Ma SP, Hasebe F, Inoue S, Makino Y, Takagi M, Nam VS, Morita K. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. J Gen Virol 2004; 85:1625-31; PMID:15166447; https://doi.org/10.1099/vir.0.79797-0
   PubMed Web of Science ®Google Scholar
• Yun SM, Cho JE, Ju YR, Kim SY, Ryou J, Han MG, Choi WY, Jeong YE. Molecular epidemiology of Japanese encephalitis virus circulating in South Korea, 1983–2005. Virol J 2010; 7:127; PMID:20546562; https://doi.org/10.1186/1743-422X-7-127
   PubMed Web of Science ®Google Scholar
• Huang JH, Lin TH, Teng H, Hsu CL, Tsai KH, Lu LC, Lin C, Yang CF, Chang SF, Liao TL, et al. Molecular epidemiology of Japanese encephalitis virus, Taiwan. Emerg Infect Dis 2010; 16:876-8; PMID:20409392; https://doi.org/10.3201/eid1605.091055
   PubMed Web of Science ®Google Scholar
• Chen YY, Fan YC, Tu WC, Chang RY, Shih CC, Lu IH, Chien MS, Lee WC, Chen TH, Chang GJ, et al. Japanese encephalitis virus genotype replacement, Taiwan, 2009–10. Emerg Infect Dis 2011; 17:2353-6
   Web of Science ®Google Scholar
• Pan XL, Liu H, Wang HY, Fu SH, Liu HZ, Zhang HL, Li MH, Gao XY, Wang JL, Sun XH, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol 2011; 85:9847-53; PMID:21697481; https://doi.org/10.1128/JVI.00825-11
   PubMed Web of Science ®Google Scholar
• Okuno Y, Okamoto Y, Yamada A, Baba K, Yabuuchi H. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus. Vaccine 1987; 5:128-32; PMID:3037813; https://doi.org/10.1016/0264-410X(87)90059-4
   PubMed Web of Science ®Google Scholar
• Shyu WR, Wang YC, Chin C, Chen WJ. Assessment of neutralizing antibodies elicited by a vaccine (Nakayama) strain of Japanese encephalitis virus in Taiwan. Epidemiol Infect 1997; 119:79-83; PMID:9287947; https://doi.org/10.1017/S095026889700753X
   PubMed Web of Science ®Google Scholar
• Susilowati S, Okuno Y, Fukunaga T, Tadano M, Juang RF, Fukai K. Neutralization antibody responses induced by Japanese encephalitis virus vaccine. Biken J 1981; 24:137-45. PMID:7346039
   PubMedGoogle Scholar
• Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, McCarthy K, Kanesa-thasan N, Meric C, Reid M. Long-term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 2010; 6:1038-46; PMID:21150279; https://doi.org/10.4161/hv.6.12.13057
   PubMed Web of Science ®Google Scholar
• Pan JR, Yan JY, Zhou JY, Tang XW, He HQ, Xie RH, Mao HY, Zhang YJ, Xie SY. Sero-molecular epidemiology of Japanese encephalitis in Zhejiang, an eastern province of China. PLoS Negl Trop Dis 2016; 10:e0004936; PMID:27560360; https://doi.org/10.1371/journal.pntd.0004936
   PubMed Web of Science ®Google Scholar
• Liu X. Yu Y, Li M, Liang G, Wang H, Jia L, Dong G. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine 2011; 29:2127-30; PMID:21237278; https://doi.org/10.1016/j.vaccine.2010.12.108
   PubMed Web of Science ®Google Scholar
• Feroldi E, Boaz M, Yoksan S, Chokephaibulkit K, Thisyakorn U, Phacharoen C, Monfredo C, Bouckenooghe A. Persistence of wild-type Japanese encephalitis virus strains cross-neutralization five years following JE-CV immunization. J Infect Dis 2016; Nov 3 [Epub ahead of print]. PMID:27815383; https://doi.org/10.1093/infdis/jiw533
   PubMed Web of Science ®Google Scholar
• Hanna JN, Smith GA, McCulloch BG, Taylor CT, Pyke AT, Brookes DL. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health 2005; 29:44-7; PMID:15782871; https://doi.org/10.1111/j.1467-842X.2005.tb00747.x
   PubMed Web of Science ®Google Scholar
• Rodrigues FM, Mohan Rao CV, Mandke VB, Pinto BD, Pavri K. Neutralizing antibody response to Japanese encephalitis inactivated mouse brain vaccine among laboratory personnel. Trans R Soc Trop Med Hyg 1986; 80:301-4; PMID:3024366; https://doi.org/10.1016/0035-9203(86)90041-6
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Hayashida K, Matsuo F, Shiosaki K, Miyazaki C, Ueda K, Kino Y. Duration of neutralizing antibody titer after Japanese encephalitis vaccination. Microbiol Immunol 2007; 51:609-16; PMID:17579272; https://doi.org/10.1111/j.1348-0421.2007.tb03947.x
   PubMed Web of Science ®Google Scholar
• Reisler RB, Danner DK, Gibbs PH. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity. Vaccine 2010; 28:243641; https://doi.org/10.1016/j.vaccine.2009.12.080
   Web of Science ®Google Scholar
• Sohn YM, Tandan JB, Yoksan S, Ji M, Ohrr H. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 2008; 26:1638-43; PMID:18294743; https://doi.org/10.1016/j.vaccine.2008.01.021
   PubMed Web of Science ®Google Scholar
• Desai K, Coudeville L, Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine 2012; 30:2510-5; PMID:22342547; https://doi.org/10.1016/j.vaccine.2012.02.005
   PubMed Web of Science ®Google Scholar
• Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenbock A, Klade C, Tauber C. Long-term immunogenicity of the new Vero cell-derived inactivated Japanese encephalitis virus vaccine IC51. Six and 12 month results of a multicentre follow-up phase 3 study. Vaccine 2008; 26:4382-6
   PubMed Web of Science ®Google Scholar
• Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine, IXIARO, IC51. Vaccine 2010; 28:5197-202; PMID:20541581; https://doi.org/10.1016/j.vaccine.2010.05.069
   PubMed Web of Science ®Google Scholar
• Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51. Vaccine 2011; 29:2607-12; PMID:21288804; https://doi.org/10.1016/j.vaccine.2011.01.058
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine 2015; 33:3600-4; PMID:26036947; https://doi.org/10.1016/j.vaccine.2015.05.037
   PubMed Web of Science ®Google Scholar
• Tang XY, Ma HX, Su C, Shang SY, Kang K, Huang XY, Yin ZD, Wang HY. Surveillance of healthy people's Japanese encephalitis neutralizing antibody in some areas of Henan province. Zhongua Shi Yan He Lin Chuang bing Du Xue Za Zhi 2011; 25:401-4
   PubMedGoogle Scholar
• Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, Lin IF, Chang FY. The incidence of Japanese encephalitis in Taiwan – a population-based study. PLoS Negl Trop Dis 2014; 8:e3030; PMID:25058573; https://doi.org/10.1371/journal.pntd.0003030
   PubMed Web of Science ®Google Scholar
• Lee EJ, Cha GW, Ju YR, Han MG, Lee WJ, Jeong YE. Prevalence of neutralizing antibodies to Japanese encephalitis virus among high-risk age groups in South Korea, 2010. PLoS ONE 2016; 11:e0147841; PMID:26807709; https://doi.org/10.1371/journal.pone.0147841
   PubMed Web of Science ®Google Scholar
• Zhang SB, Li P, Liu XZ. Analysis on neutralization antibody titer of Japanese B encephalitis virus in healthy population in Shaanxi province. Zhongguo Yi Miao He Mian Yi 2010; 16:251-3. PMID:20726269
   PubMedGoogle Scholar
• Quina MA, Thein S, Auvanich W, Okuno Y, Igarashi A, Fukai K. Changes in dengue and Japanese encephalitis (JE) antibody after JE vaccination. Biken J. 1978; 21:149-59. PMID:754688
   PubMedGoogle Scholar
• Nasveld PE, Marjason J, Bennett S, Asskov J, Elliott S, McCarthy K, Kanesa-thasan N, Feroldi E, Reid M. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin 2010; 6:906-14; PMID:20864814; https://doi.org/10.4161/hv.6.11.12854
   PubMed Web of Science ®Google Scholar
• Chan KR, Wang X, Saron WA, Gan ES, Tan HC, Mok DZ, Zhang SL, Lee YH, Liang C, Wijaya L, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol 2016; Sep 19 [Epub ahead of print]; PMID: 27642668; https://doi.org/1038/nmicrobiol.2016.164
   Web of Science ®Google Scholar
• Yang SE, Pan MJ, Tseng HF, Liau MY. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine – results from 30 years' experience in Taiwan. Vaccine 2006; 24:2669-73; PMID:16314007; https://doi.org/10.1016/j.vaccine.2005.10.054
   PubMed Web of Science ®Google Scholar
• Marks F, Nguyen TT, Tran ND, Nguyen MH, Vu HH, Meyer CG, You YA, Konings F, Liu W, Wierzba TF, et al. Effectiveness of the Viet Nam produced, mouse brain-derived, inactivated Japanese encephalitis vaccine in Northern Viet Nam. PLoS Negl Trop Dis 2012; 6:e1952; PMID:23272262; https://doi.org/10.1371/journal.pntd.0001952
   PubMed Web of Science ®Google Scholar
• Muangchana C, Henprasertthae N, Nurach K, Theppang K, Yoocharoen P, Varinsathien P, Techathawat S, Sanohsieng S, Ananaprecha S. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case-control study. Vaccine 2012; 30:361-7; PMID:22075090; https://doi.org/10.1016/j.vaccine.2011.10.083
   PubMed Web of Science ®Google Scholar
• Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB. Single dose of SA-14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007; 25:5041-5; PMID:17521781; https://doi.org/10.1016/j.vaccine.2007.04.052
   PubMed Web of Science ®Google Scholar
• Kumar R, Tripathi P, Rizvi A, Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009; 360:1465-6; PMID:19339732; https://doi.org/10.1056/NEJMc0808664
   PubMed Web of Science ®Google Scholar
• Murhekar MV, Ranjan P, Selvaraju S, Pandey A, Gore MM, Mehendele SM. Low coverage and acceptable effectiveness of single dose of Japanese encephalitis vaccine, Gorakhpur division, Uttar Pradesh, India, 2013. J Infect 2014; 69:517-20
   PubMed Web of Science ®Google Scholar
• Li X, Gao X, Ren Z, Cao Y, Wang J, Liang G. A spatial and temporal analysis of Japanese encephalitis in mainland China, 1963-1975: a period without Japanese encephalitis vaccination. PLoS ONE 2014; 9:e99183; PMID:24911168; https://doi.org/10.1371/journal.pone.0099183
   PubMed Web of Science ®Google Scholar
• Wang H, Li Y, Liang X, Liang G. Japanese encephalitis in mainland China. Jpn J Infect Dis 2009; 62:331-6. PMID:19762980
   PubMed Web of Science ®Google Scholar
• Zhang L, Luan RS, Jiang F, Rui LP, Liu M, Li YX, Yin ZD, Luo HM. Epidemiological characteristics of Japanese encephalitis in Guizhou Province, China, 1971–2009. Biomed Environ Sci 2012; 25:297-304. PMID:22840580
   PubMed Web of Science ®Google Scholar
• Ranjan P, Gore M, Selvaraju S, Kushwaha KP, Srivastava DK, Murhekar M. Changes in acute encephalitis syndrome incidence after introduction of Japanese encephalitis vaccine in a region in India. J Infect 2014; 69:200-2; PMID:24657663; https://doi.org/10.1016/j.jinf.2014.03.013
   PubMed Web of Science ®Google Scholar
• Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, Kurane I. Vaccine preventable diseases surveillance program of Japan. Jpn J Infect Dis 2008; 61:333-8. PMID:18806337
   PubMed Web of Science ®Google Scholar
• Satou K, Nishiura H. Evidence of the partial effects of inactivated Japanese encephalitis vaccination: analysis of previous outbreaks in Japan from 1953 to 1960. Ann Epidemiol 2007; 17:271-7; PMID:17300956; https://doi.org/10.1016/j.annepidem.2006.10.003
   PubMed Web of Science ®Google Scholar
• Impoinvil DE, Ooi MH, Diggle PJ, Caminade C, Cardosa MJ, Morse AP, Baylis M, Solomon T. The effect of vaccination coverage and climate on Japanese encephalitis in Sarawak, Malaysia. PLoS Negl Trop Dis 2013; 7:e2334; PMID:23951373; https://doi.org/10.1371/journal.pntd.0002334
   PubMed Web of Science ®Google Scholar
• Dumre SP, Shakya G, Na-Bangchang K, Eursitthichai V, Rudi Grams H, Upreti SR, Ghimire P, Khagendra KC, Nisalak A, Gibbons RV, et al. Dengue virus and Japanese encephalitis virus epidemiological shifts in Nepal: a case of opposing trends. Am J Trop Med Hyg 2013; 88:677-80; PMID:23419366; https://doi.org/10.4269/ajtmh.12-0436
   PubMed Web of Science ®Google Scholar
• Upreti SR, Janusz KB, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, Shrestha MM, Sedai TR, Fischer M, Gibbons RV, et al. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal. Am J Trop Med Hyg 2013; 88:464-8; PMID:23358643; https://doi.org/10.4269/ajtmh.12-0196
   PubMed Web of Science ®Google Scholar
• De Alwis KN, Abeysinghe MR, Wickramesinghe AR, Wijesinghe PR. A cohort event monitoring to determine the adverse events following administration of mouse brain derived, inactivated Japanese encephalitis vaccine in an endemic district in Sri Lanka. Vaccine 2014; 32:924-30; PMID:24406391; https://doi.org/10.1016/j.vaccine.2013.12.047
   PubMed Web of Science ®Google Scholar
• Okuno T, Tseng PT, Hsu ST, Huang CT, Kuo CC. Japanese encephalitis surveillance in China (Province of Taiwan) during 1968–1971. II. Age-specific incidence in connection with Japanese encephalitis vaccination program. Jpn J Med Sci Biol 1975; 28:255-67; PMID:180320; https://doi.org/10.7883/yoken1952.28.255
   PubMedGoogle Scholar
• Hsu LC, Chen YJ, Hsu FK, Huang JH, Chang CM, Chou P, Lin IF, Chang FY. The incidence of Japanese encephalitis in Taiwan – a population-based study. PLoS Negl Trop Dis 2014; 8:e3030; PMID:25058573; https://doi.org/10.1371/journal.pntd.0003030
   PubMed Web of Science ®Google Scholar
• Wierzba TF, Ghimire P, Malla S, Banerjee MK, Shrestha S, Khanal B, Sedai TR, Gibbons RV. Laboratory-based Japanese encephalitis surveillance in Nepal and the implications for a national immunization strategy. Am J Trop Hyg 2008; 78:1002-6
   PubMed Web of Science ®Google Scholar
• Impoinvil DE, Solomon T, Schluter WW, Rayamajhi A, Bichha TP, Shakya G, Caminade C, Baylis M. The spatial heterogeneity between Japanese encephalitis incidence distribution and environmental variables in Nepal. PLoS ONE 2011; 6:e22192; PMID:21811573; https://doi.org/10.1371/journal.pone.0022192
   PubMed Web of Science ®Google Scholar
• Wong SC, Ooi MH, Abdullah AR, Wong SY, Krishnan S, Tio PH, Pek PC, Lai BF, Mohan A, Muhi J, et al. A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997–2006. Trop Med Int Health 2008; 13:52-5; PMID:18291002; https://doi.org/10.1111/j.1365-3156.2007.01967.x
   PubMed Web of Science ®Google Scholar
• Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. Southeast Asian J Trop Med Public Health 1997; 28:143-8. PMID:9322297
   PubMedGoogle Scholar
• Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull World Health Organ 2003; 81:334-42. PMID:12856051
   PubMed Web of Science ®Google Scholar
• Yin Z, Beeler Asay GR, Zhang L, Li Y, Zou S, Hutin YJ, Ning G, Sandhu HS, Cairns L, Luo H, Guizhou Japanese encephalitis Study Group. An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. Vaccine 2012; 30:5569-77; PMID:22698453; https://doi.org/10.1016/j.vaccine.2012.05.068
   PubMed Web of Science ®Google Scholar
• Liu W, Clemens JD, Kari K, Xu ZY. Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine 2008; 26:4456-60; PMID:18602436; https://doi.org/10.1016/j.vaccine.2008.06.050
   PubMed Web of Science ®Google Scholar
• Touch S, Suraratdecha C, Samnang C, Heng S, Gazley L, Huch C, Sovan L, Chhay CS, Soeung SC. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine 2010; 28:4593-9; PMID:20470803; https://doi.org/10.1016/j.vaccine.2010.04.086
   PubMed Web of Science ®Google Scholar
• Singh K. Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India: a cost-benefit study. J Vector Borne Dis 2014; 51:47-52. PMID:24717202
   PubMed Web of Science ®Google Scholar
• Suraratdecha C, Levin C, Jacobson J, La Force M. Demand-driven and affordable next generation vaccines for preventing Japanese encephalitis in Asia and meningococcal meningitis in Sub-Saharan Africa. Presented at: Sixth International Health Economics Association World Congress; Explorations in health economics, July 2007; Copenhagen, Denmark
   Google Scholar
• Wang S-Y, Cheng X-H, Li J-X, Li X-Y, Zhu F-C, Liu P. Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: a systematic review and meta-analysis. Human Vac Immunother 2015; 11:1418-25; https://doi.org/10.1080/21645515.2015.1011996
   PubMed Web of Science ®Google Scholar
• Melian EB, Hinzman E, Nagasaki T, Firth AE, Wills NM, Nouwens AS, Blitvich BJ, Leung J, Funk A, Atkins JF, et al. NS1′ of flaviviruses in the Japanese encephalitis virus serogroup is a product of ribosomal frameshifting and plays a role in viral neuroinvasiveness. J. Virol. 2010; 84:1641-7; PMID:19906906; https://doi.org/10.1128/JVI.01979-09
   PubMed Web of Science ®Google Scholar
• Melian EB, Hall-Mendelin S, Du F, Owens N, Bosco-Lauth AM, Nagasaki T, Rudd S, Brault AC, Bowen RA, Hall RA, et al. Programmed ribosomal frameshift alters expression of West Nile virus genes and facilitates virus replication in birds and mosquitoes. PLoS Pathog 2014; 10:e1004447; PMID:25375107; https://doi.org/10.1371/journal.ppat.1004447
   PubMed Web of Science ®Google Scholar